The data illustrates a pharmaceutical company ranking based on R&D for developing countries in 2016, according to the Access to Medicine Index 2016. In that year, the leading company concerning research and development for these markets was GlaxoSmithKline with an indicator score of 3.6 points. The Access to Medicine Index is an independent
initiative that ranks the world’s
20 biggest companies according to their
efforts to make their products more available,
affordable and accessible in developing
countries, highlighting policy and
practice that either facilitate or hinder
access to medicine.
